Glyburide
- Generic Name
- Glyburide
- Brand Names
- Diabeta, Glucovance, Glynase, Amglidia
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28ClN3O5S
- CAS Number
- 10238-21-8
- Unique Ingredient Identifier
- SX6K58TVWC
- Background
Glyburide is a second generation sulfonylurea used to treat patients with diabetes mellitus type II. It is typically given to patients who cannot be managed with the standard first line therapy, metformin. Glyburide stimulates insulin secretion through the closure of ATP-sensitive potassium channels on beta cells, raising intracellular potassium and calcium ...
- Indication
Glyburide is indicated alone or as part of combination product with metformin, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Gestational Diabetes Mellitus (GDM), Glycemic Control, Type 2 Diabetes Mellitus
- Associated Therapies
- -
GALLANT 4 Tesaglitazar vs. Glibenclamide
- Conditions
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2008-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 580
- Registration Number
- NCT00255541
- Locations
- 🇹🇭
Research Site, Bangkok, Thailand
Preservation of Beta-cell Function in Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2017-12-14
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 58
- Registration Number
- NCT00232583
- Locations
- 🇺🇸
University of Texas Southwestern, Dallas, Texas, United States
Preferred Treatment of Type 1.5 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 64
- Registration Number
- NCT00194896
- Locations
- 🇺🇸
DVA Puget Sound Health Care System, Seattle, Washington, United States
Ischemic Injury and Ischemic Preconditioning in Diabetes
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2007-04-05
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT00184821
- Locations
- 🇳🇱
Clinical Research Centre Nijmegen; Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands
Glyburide Compared to Insulin in the Management of White's Classification A2 Gestational Diabetes
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-02-11
- Lead Sponsor
- Tripler Army Medical Center
- Registration Number
- NCT00160485
- Locations
- 🇺🇸
Tripler Army Medical Center, Honolulu, Hawaii, United States
Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients
- First Posted Date
- 2005-07-25
- Last Posted Date
- 2013-07-15
- Lead Sponsor
- St. Paul Heart Clinic
- Target Recruit Count
- 36
- Registration Number
- NCT00123643
- Locations
- 🇺🇸
St. Paul Heart Clinic, St. Paul, Minnesota, United States
Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment
- Conditions
- First Posted Date
- 2002-10-02
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 240
- Registration Number
- NCT00046462
- Locations
- 🇺🇸
Aventis, Bridgewater, New Jersey, United States
A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes.
- Conditions
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2011-04-15
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00035542
- Locations
- 🇺🇸
National Institute Of Clinical Research, Los Angeles, California, United States
🇺🇸Driscoll Children's Hospital/Division of Medical Education/William Riley, Corpus Christi, Texas, United States
🇺🇸Metro Health Medical Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.